First-In-Human Study Of Abbv-637, An Egfr-Targeting Bcl-Xl-Inhibiting Antibody-Drug Conjugate Combined With Osimertinib (Osi) In Relapsed/Refractory, Egfr-Mutated Non-Small Cell Lung Cancer (Nsclc)
ABBV-637;Osimertinib
Below is an instruction that describes a task, paired with an input that provides further context. Write a response that appropriately completes the request. ### Instruction: Identify all the mentioned drugs in the given text. Text may or may not contain drug. If they contain more than 1 drug, use ";" as delimiter and join them. ### Input: First-In-Human Study Of Abbv-637, An Egfr-Targeting Bcl-Xl-Inhibiting Antibody-Drug Conjugate Combined With Osimertinib (Osi) In Relapsed/Refractory, Egfr-Mutated Non-Small Cell Lung Cancer (Nsclc) ### Output: ABBV-637;Osimertinib